News J&J's nipocalimab fast-tracked for Sjogren's disease Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.
News UK partners with Eli Lilly on obesity plan The UK has teamed up with Eli Lilly on initiatives, backed with £85 million in funding, to expand access to treatment for obesity.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
